Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has Kala Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KALA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: KALA's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: KALA underperformed the US Pharmaceuticals industry which returned 14.6% over the past year.
Return vs Market: KALA underperformed the US Market which returned 38.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kala Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StAre Institutions Heavily Invested In Kala Pharmaceuticals, Inc.'s (NASDAQ:KALA) Shares?
1 month ago | Simply Wall StReflecting on Kala Pharmaceuticals' (NASDAQ:KALA) Share Price Returns Over The Last Three Years
2 months ago | Simply Wall StIs Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Is Kala Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: KALA ($5.86) is trading below our estimate of fair value ($50.37)
Significantly Below Fair Value: KALA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: KALA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: KALA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KALA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KALA is overvalued based on its PB Ratio (3.4x) compared to the US Pharmaceuticals industry average (3.3x).
How is Kala Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KALA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: KALA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: KALA's is expected to become profitable in the next 3 years.
Revenue vs Market: KALA's revenue (56.1% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: KALA's revenue (56.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KALA's Return on Equity is forecast to be high in 3 years time
How has Kala Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KALA is currently unprofitable.
Growing Profit Margin: KALA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KALA is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare KALA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KALA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: KALA has a negative Return on Equity (-102.73%), as it is currently unprofitable.
How is Kala Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: KALA's short term assets ($179.1M) exceed its short term liabilities ($20.0M).
Long Term Liabilities: KALA's short term assets ($179.1M) exceed its long term liabilities ($100.0M).
Debt to Equity History and Analysis
Debt Level: KALA's debt to equity ratio (66.1%) is considered high.
Reducing Debt: KALA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KALA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if KALA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Kala Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KALA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KALA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KALA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KALA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KALA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Iwicki (54 yo)
Mr. Mark T. Iwicki has been the Chairman and Independent Director of Aerovate Therapeutics, Inc. since February 2021. Mr. Iwicki is Director at Q32 Bio Inc. He has been the Chief Executive Officer and Chai...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD4.90M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Experienced Management: KALA's management team is considered experienced (3.9 years average tenure).
Experienced Board: KALA's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16%.
Kala Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Kala Pharmaceuticals, Inc.
- Ticker: KALA
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$369.108m
- Shares outstanding: 64.64m
- Website: https://www.kalarx.com
Number of Employees
- Kala Pharmaceuticals, Inc.
- 490 Arsenal Way
- Suite 120
- United States
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP)...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/22 03:11|
|End of Day Share Price||2021/06/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.